MedTrace Logo

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

NCT07213791 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 241

Last updated 2026-05-22

No results posted yet for this study

Summary

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.

Conditions

  • Ovarian Neoplasms
  • Breast Neoplasms
  • Pancreatic Intraductal Neoplasms
  • Colorectal Neoplasms
  • Esophageal Neoplasms
  • Stomach Neoplasms
  • Cholangiocarcinoma

Interventions

DRUG

LY4337713

Administered IV.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-22
Primary Completion
2028-07-31
Completion
2033-03-31
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Japan
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07213791 on ClinicalTrials.gov